Core Insights - Cryoport Systems' Safepak® Soft System 1800 has been awarded "BioServices Innovation of the Year" by BioTech Breakthrough, recognizing its advancements in temperature-controlled supply chain solutions for life sciences [1][8] - The Safepak Soft System 1800 is designed to enhance the safety and efficiency of transporting biologic payloads, addressing critical weaknesses in traditional cryogenic transport systems [5][8] Company Overview - Cryoport, Inc. (Nasdaq: CYRX) is a leading provider of temperature-controlled supply chain solutions, focusing on regenerative medicine and supporting various stakeholders in the life sciences sector [11] - The company offers a comprehensive suite of services and products aimed at minimizing risk and maximizing reliability across the temperature-controlled supply chain [11] Product Features - The Safepak Soft System 1800 incorporates patent-pending SoftRack technology, which immobilizes and cushions biologic payloads during shipment, significantly reducing the risk of damage [3][8] - It features an ultra-absorbent containment bag with a capacity of up to 1,800 mL, providing superior protection against leakage [3] - The system is validated for use with the Cryoport Express® Cryogenic HV3 Shipping System and complies with global shipping standards, ensuring regulatory readiness [4][8] Industry Context - The biotechnology sector is rapidly evolving, driving innovation in healthcare, agriculture, and life sciences, with a focus on advanced therapies and sustainable solutions [6] - The BioTech Breakthrough Awards program serves as a global recognition platform, highlighting top companies and innovations in the life sciences and biotechnology markets [7]

Core Insights - Cryoport, Inc. has launched a new state-of-the-art facility in Louvres, France, enhancing its Global Supply Chain Center network to support complex life sciences supply chain needs [1][2][4] - The facility is strategically located near Paris Charles de Gaulle Airport and will provide end-to-end temperature-controlled supply chain solutions for biopharma and other temperature-sensitive commodities [2][3] - The facility will be operational immediately, offering logistics support for various therapies and will expand its services over time to include BioServices and biostorage [3][4] Company Expansion - The new facility is the third global supply chain center in Cryoport's network, aimed at streamlining operations in the advanced therapies market [2] - It will enhance Cryoport's ability to serve clients in European and global markets, ensuring secure handling of temperature-sensitive commodities [4] - The facility's operations will include 24-hour worldwide dispatch capabilities and will align with Cryoport's quality oversight standards [4] Future Developments - An official grand opening for the Paris GSCC is scheduled for November 20, 2025, which will involve local dignitaries and market leaders in the advanced therapies sector [5] - The facility was partially funded by a grant from the Île-de-France region to promote economic growth in the area [4]

Core Insights - Cryoport, Inc. reported strong financial results for Q2 and H1 2025, with total revenue from continuing operations increasing by 14% year-over-year to $45.5 million in Q2 and 12% to $86.5 million in H1 [10][19][20] - The company achieved double-digit growth across all revenue streams within Life Sciences Services, with a notable 21% increase year-over-year [2][4] - A strategic partnership with DHL Group was launched, enhancing Cryoport's global biologistics capabilities and providing a strong capital infusion [5][10] Financial Performance - Life Sciences Services revenue for Q2 2025 was $24.4 million, up 21% from $20.2 million in Q2 2024, and accounted for 54% of total revenue [19][10] - BioLogistics Solutions revenue increased by 20% year-over-year to $19.9 million, while BioStorage/BioServices revenue rose 28% to $4.5 million [19][10] - Life Sciences Products revenue grew 8% year-over-year to $21.1 million [19][10] Profitability Metrics - Gross margin from continuing operations improved to 47.0% in Q2 2025, compared to 44.5% in Q2 2024 [19][10] - Adjusted EBITDA was a negative $0.9 million for Q2 2025, an improvement from negative $5.6 million in Q2 2024 [21][10] Strategic Developments - The company supported 728 global clinical trials as of June 30, 2025, a net increase of 44 trials from the previous year [7][9] - Cryoport's customer, Abeona Therapeutics, received FDA approval for their cell therapy ZEVASKYNTM during the quarter [9][10] Guidance and Future Outlook - Cryoport reaffirmed its full-year 2025 revenue guidance, expecting total revenue from continuing operations to be in the range of $165 million to $172 million, representing 5% to 10% growth year-over-year [24][10] - The company anticipates additional application filings and therapy approvals in the remainder of 2025 [11][10]

NASHVILLE, Tenn., July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2025 on Tuesday, August 5, 2025 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Second Quarter 2025 in Review", providing a review of Cryoport's financial and operational ...

Core Insights - Cryoport, Inc. has completed the divestiture of its specialty courier business, CRYOPDP, to DHL Group for approximately $200 million in cash [1][4] - A strategic partnership has been established between Cryoport and DHL to enhance supply chain services in the global life sciences and healthcare sector [2][3] Financial Impact - The divestiture provides a significant capital infusion, improving Cryoport's growth trajectory and positioning the company for sustainable, long-term profitability [4] Strategic Focus - The partnership with DHL is expected to enhance Cryoport's capabilities in the Asia Pacific and EMEA regions, allowing for targeted services in response to market demand [3] - Cryoport aims to intensify its focus on advancing its Life Science Services platform, particularly in the regenerative medicine market [3] Company Overview - Cryoport is a leader in temperature-controlled supply chain solutions for the life sciences, emphasizing regenerative medicine [5] - The company offers a comprehensive suite of services designed to minimize risk and maximize reliability across the temperature-controlled supply chain [5]

Core Viewpoint - Cryoport, Inc. reported a strong start to 2025 with a revenue of $41.0 million for Q1, reflecting a 10% year-over-year growth, and expressed optimism for the full year due to stabilizing order patterns and increased engagement in its Life Sciences Services segment [2][6][19]. Financial Performance - Total revenue from continuing operations for Q1 2025 was $41.0 million, up from $37.3 million in Q1 2024, marking a 10.1% increase [14]. - Life Sciences Services revenue, which constituted 56% of total revenue, reached $22.9 million, a 17.3% increase year-over-year [14]. - Life Sciences Products revenue, representing 44% of total revenue, was $18.2 million, showing a 2.1% increase compared to the previous year [14]. - Adjusted EBITDA for Q1 2025 was a negative $2.8 million, an improvement from a negative $6.7 million in Q1 2024 [16][38]. - The net loss for Q1 2025 was $12.0 million, compared to a net loss of $18.9 million in Q1 2024 [24]. Business Segments - Revenue from commercial Cell & Gene therapies increased by 33% year-over-year, totaling $7.2 million [8][9]. - Life Sciences Services revenue increased by 17% year-over-year, driven by the development and commercialization of Cell & Gene-based therapies [3][9]. - BioStorage/BioServices revenue grew by 23% year-over-year, indicating strong demand for these services [7]. Strategic Developments - Cryoport announced a strategic partnership with DHL Group, which includes the anticipated acquisition of CRYOPDP, expected to close in Q2 or Q3 2025 [5][11]. - The partnership is expected to enhance operational reach in the APAC and EMEA regions and provide a strong infusion of capital [5][11]. Market Position and Outlook - The company supports 711 global clinical trials as of March 31, 2025, an increase of 36 trials from the previous year [9]. - The company anticipates continued growth in the regenerative medicine space and aims to return to positive adjusted EBITDA during 2025 [6][19].

Core Viewpoint - Cryoport, Inc. is set to report its financial results for the first quarter of 2025 on May 7, 2025, after U.S. markets close, highlighting its ongoing commitment to transparency and communication with investors [1][2]. Financial Reporting - The earnings release will be accompanied by a document titled "Cryoport First Quarter 2025 in Review," which will provide insights into the company's financial and operational performance, as well as a general business update [2]. - A conference call will be held on the same day at 5:00 p.m. ET, allowing members of the investment community to ask questions regarding the reported results [3]. Conference Call Details - The conference call is scheduled for May 7, 2025, at 5:00 p.m. ET, with dial-in numbers provided for both U.S. and international participants [4]. - A slide deck will accompany the call, and the session will be recorded for later access, ensuring that stakeholders can review the information at their convenience [4]. Company Overview - Cryoport, Inc. is a global leader in temperature-controlled supply chain solutions for the life sciences sector, focusing on regenerative medicine [5]. - The company offers a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain, including advanced packaging, informatics, and biostorage solutions [5]. - Cryoport operates globally with headquarters in Nashville, Tennessee, and additional sites across the Americas, EMEA, and APAC regions [5].